These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 36129324)

  • 21. ApoCIII as a Cardiovascular Risk Factor and Modulation by the Novel Lipid-Lowering Agent Volanesorsen.
    Rocha NA; East C; Zhang J; McCullough PA
    Curr Atheroscler Rep; 2017 Nov; 19(12):62. PubMed ID: 29124482
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Familial chylomicronemia syndrome: an under-recognized cause of severe hypertriglyceridaemia.
    Baass A; Paquette M; Bernard S; Hegele RA
    J Intern Med; 2020 Apr; 287(4):340-348. PubMed ID: 31840878
    [TBL] [Abstract][Full Text] [Related]  

  • 23. N-3 fatty acids from fish oil. Effects on plasma lipoproteins and hypertriglyceridemic patients.
    Connor WE; DeFrancesco CA; Connor SL
    Ann N Y Acad Sci; 1993 Jun; 683():16-34. PubMed ID: 8352438
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Volanesorsen to treat severe hypertriglyceridaemia: A pooled analysis of randomized controlled trials.
    Calcaterra I; Lupoli R; Di Minno A; Di Minno MND
    Eur J Clin Invest; 2022 Nov; 52(11):e13841. PubMed ID: 35851450
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterizing familial chylomicronemia syndrome: Baseline data of the APPROACH study.
    Blom DJ; O'Dea L; Digenio A; Alexander VJ; Karwatowska-Prokopczuk E; Williams KR; Hemphill L; Muñiz-Grijalvo O; Santos RD; Baum S; Witztum JL
    J Clin Lipidol; 2018; 12(5):1234-1243.e5. PubMed ID: 30318066
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of antisense oligonucleotide therapy against apolipoprotein-CIII in hypertriglyceridemia.
    Gouni-Berthold I
    Atheroscler Suppl; 2017 Nov; 30():19-27. PubMed ID: 29096837
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent advances in treating hypertriglyceridemia in patients at high risk of cardiovascular disease with apolipoprotein C-III inhibitors.
    Spagnuolo CM; Hegele RA
    Expert Opin Pharmacother; 2023 Jun; 24(9):1013-1020. PubMed ID: 37114828
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: Results of the BROADEN study: Volanesorsen in FPLD; The BROADEN Study.
    Oral EA; Garg A; Tami J; Huang EA; O'Dea LSL; Schmidt H; Tiulpakov A; Mertens A; Alexander VJ; Watts L; Hurh E; Witztum JL; Geary RS; Tsimikas S
    J Clin Lipidol; 2022; 16(6):833-849. PubMed ID: 36402670
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Significant Quality of Life Improvement Observed in a Patient With FCS Associated With a Marked Reduction in Triglycerides.
    Gouni-Berthold I
    J Endocr Soc; 2020 Feb; 4(2):bvz035. PubMed ID: 32083235
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Updates in Drug Treatment of Severe Hypertriglyceridemia.
    Gouni-Berthold I; Schwarz J; Berthold HK
    Curr Atheroscler Rep; 2023 Oct; 25(10):701-709. PubMed ID: 37642858
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of omega-3 supplements on plasma apolipoprotein C-III concentrations: a systematic review and meta-analysis of randomized controlled trials.
    Sahebkar A; Simental-Mendía LE; Mikhailidis DP; Pirro M; Banach M; Sirtori CR; Reiner Ž
    Ann Med; 2018 Nov; 50(7):565-575. PubMed ID: 30102092
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature.
    Ito MK
    Atherosclerosis; 2015 Oct; 242(2):647-56. PubMed ID: 26296750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. APOC-III Antisense Oligonucleotides: A New Option for the Treatment of Hypertriglyceridemia.
    Schmitz J; Gouni-Berthold I
    Curr Med Chem; 2018; 25(13):1567-1576. PubMed ID: 28595549
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Comprehensive Update on the Chylomicronemia Syndrome.
    Goldberg RB; Chait A
    Front Endocrinol (Lausanne); 2020; 11():593931. PubMed ID: 33193106
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Symptoms and impacts of familial chylomicronemia syndrome: a qualitative study of the patient experience.
    Williams K; Tickler G; Valdivielso P; Alonso J; Vera-Llonch M; Cubells L; Acaster S
    Orphanet J Rare Dis; 2023 Oct; 18(1):316. PubMed ID: 37817256
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of Hypertriglyceridemia: A Review of Therapies in the Pipeline.
    Xu J; Ashjian E
    J Pharm Pract; 2023 Jun; 36(3):650-661. PubMed ID: 34720008
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Familial chylomicronemia].
    Quiroga-Padilla PJ; Gaete PV; Mendivil CO
    Medicina (B Aires); 2020; 80(4):348-358. PubMed ID: 32841138
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results.
    Yang X; Lee SR; Choi YS; Alexander VJ; Digenio A; Yang Q; Miller YI; Witztum JL; Tsimikas S
    J Lipid Res; 2016 Apr; 57(4):706-13. PubMed ID: 26848137
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolism and Disposition of Volanesorsen, a 2'-
    Post N; Yu R; Greenlee S; Gaus H; Hurh E; Matson J; Wang Y
    Drug Metab Dispos; 2019 Oct; 47(10):1164-1173. PubMed ID: 31350288
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Familial chylomicronemia syndrome due to a heterozygous deletion of the chromosome 8 treated with the apoCIII inhibitor volanesorsen: A case report.
    Tünnemann-Tarr A; Scharnagl H; Katzmann JL; Stürzebecher P; Laufs U
    Medicine (Baltimore); 2021 Oct; 100(42):e27573. PubMed ID: 34678899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.